MA40894A - Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production - Google Patents
Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de productionInfo
- Publication number
- MA40894A MA40894A MA040894A MA40894A MA40894A MA 40894 A MA40894 A MA 40894A MA 040894 A MA040894 A MA 040894A MA 40894 A MA40894 A MA 40894A MA 40894 A MA40894 A MA 40894A
- Authority
- MA
- Morocco
- Prior art keywords
- lymphocytes
- target
- production processes
- heterodimeric immunoglobulins
- heterodimeric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/073738 WO2015063339A1 (fr) | 2013-11-04 | 2014-11-04 | Production de cellules t reciblant des immunoglobulines héréro-dimériques |
| EP15167034 | 2015-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40894A true MA40894A (fr) | 2017-09-12 |
Family
ID=53059011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040894A MA40894A (fr) | 2014-11-04 | 2015-11-02 | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP3215541A1 (fr) |
| JP (3) | JP2018501297A (fr) |
| KR (1) | KR102760422B1 (fr) |
| CN (1) | CN107207596A (fr) |
| AU (1) | AU2015341884B2 (fr) |
| BR (1) | BR112017009263A2 (fr) |
| CA (1) | CA2965745C (fr) |
| CL (1) | CL2017001090A1 (fr) |
| CO (1) | CO2017005240A2 (fr) |
| EA (1) | EA039658B1 (fr) |
| HK (1) | HK1244014A1 (fr) |
| IL (1) | IL251848A0 (fr) |
| MA (1) | MA40894A (fr) |
| MX (1) | MX2017005814A (fr) |
| MY (1) | MY186929A (fr) |
| NZ (1) | NZ732019A (fr) |
| PE (1) | PE20171041A1 (fr) |
| PH (1) | PH12017500819A1 (fr) |
| SG (1) | SG11201703313SA (fr) |
| WO (1) | WO2016071355A1 (fr) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| CN105722859B (zh) | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| JP2016538275A (ja) | 2013-11-04 | 2016-12-08 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造 |
| EP3699195A3 (fr) | 2014-03-28 | 2020-11-04 | Xencor, Inc. | Anticorps bispécifiques se liant à cd38 et cd3 |
| CA2955947A1 (fr) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispecifiques, anticorps anti-cd3 activables multispecifiques et procedes d'utilisation de ces anticorps |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| EP3223907A2 (fr) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Anticorps hétérodimériques se liant aux antigènes cd3 et cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| CA3007030A1 (fr) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Anticorps heterodimees se liant a cd3 et psma |
| EA201891753A1 (ru) | 2016-02-03 | 2019-01-31 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки |
| JP7010854B2 (ja) | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| CN109715663B (zh) | 2016-06-28 | 2022-11-25 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
| CA3060190A1 (fr) * | 2017-04-24 | 2018-11-01 | Ichnos Sciences SA | Anticorps bispecifiques de redirection de lymphocytes t pour le traitement de cancers positifs de l'egfr |
| EP3634998B8 (fr) * | 2017-06-05 | 2025-04-09 | Numab Therapeutics AG | Anticorps anti cd3 epsilon |
| WO2018224441A1 (fr) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Nouveaux anticorps anti-cd3 |
| CN110997722B (zh) * | 2017-06-08 | 2023-09-26 | 黑带医疗有限公司 | Cd38调节抗体 |
| JP7679196B2 (ja) | 2017-06-08 | 2025-05-19 | ブラック ベルト セラピューティクス リミテッド | Ｃｄ３８調節抗体 |
| HUE065510T2 (hu) * | 2017-08-10 | 2024-05-28 | Grifols Diagnostic Solutions Inc | Immunglobulin Fc-régiót és poli-His domént tartalmazó oligomerizációs címke |
| CA3073085A1 (fr) | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Anticorps modulateur cd38 |
| KR102770110B1 (ko) | 2017-08-16 | 2025-02-20 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 항체 |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| WO2019035938A1 (fr) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à bcma et leurs utilisations |
| EP3694885A1 (fr) | 2017-10-14 | 2020-08-19 | CytomX Therapeutics, Inc. | Anticorps, anticorps activables, anticorps bispécifiques, et anticorps activables bispécifiques et leurs procédés d'utilisation |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| CA3096052A1 (fr) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Anticorps heterodimeres qui se lient a la proteine d'activation des fibroblastes |
| CA3113756A1 (fr) * | 2018-09-25 | 2020-04-02 | Ichnos Sciences S.A. | Quantification d'anticorps dans des echantillons biologiques |
| KR102353568B1 (ko) | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편 |
| SG11202107941TA (en) * | 2019-01-23 | 2021-08-30 | Encefa | Cd31 competitors and uses thereof |
| WO2020182984A2 (fr) * | 2019-03-13 | 2020-09-17 | Ichnos Sciences SA | Glycosylation sans consensus d'anticorps bispécifiques |
| TWI899079B (zh) * | 2019-05-23 | 2025-10-01 | 美商維洛斯生物公司 | 抗ror1/抗cd3雙特異性結合分子 |
| US20220227887A1 (en) * | 2019-06-11 | 2022-07-21 | Ono Pharmaceutical Co., Ltd. | Immunosuppressant |
| CN110551222B (zh) * | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | 一种新型双功能抗体及其用途 |
| CN112538114B (zh) * | 2019-09-20 | 2025-05-02 | 上海普铭生物科技有限公司 | 抗人cd38抗体及其应用 |
| TWI841790B (zh) * | 2019-09-30 | 2024-05-11 | 大陸商和鉑醫藥（上海）有限責任公司 | 靶向cd3的抗體、雙特異性抗體及其用途 |
| CN115362346A (zh) | 2020-03-19 | 2022-11-18 | 深圳纽迪瑞科技开发有限公司 | 一种应变感测膜、压力传感器、混合应变感测系统 |
| CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| EP4139347A4 (fr) * | 2020-04-24 | 2024-06-05 | Memorial Sloan Kettering Cancer Center | Anticorps anti-cd3 et utilisations associées |
| WO2021231976A1 (fr) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3 |
| US20230312742A1 (en) * | 2020-06-17 | 2023-10-05 | Y-Mabs Therapeutics, Inc. | CD38 antibodies for the treatment of human diseases |
| CA3192204A1 (fr) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anticorps anti-cd28 et/ou compositions anti-b7h3 |
| US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
| EP4305065A1 (fr) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Anticorps hétérodimères qui se lient au cd3 et au gpc3 |
| EP4380631A4 (fr) * | 2021-08-04 | 2025-06-25 | Abpro Corporation | Anticorps ciblant cd3 et leurs utilisations |
| CN118108852B (zh) * | 2023-11-23 | 2025-11-18 | 浙江大学 | 一种抗啶虫脒单克隆抗体及其重组全长IgG表达质粒 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140066259A (ko) * | 2004-02-06 | 2014-05-30 | 모르포시스 아게 | 항-ｃｄ３８ 인간 항체 및 그의 용도 |
| JP5225069B2 (ja) * | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| CA2625681C (fr) * | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain |
| EP1914242A1 (fr) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
| MY192182A (en) * | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2785414C (fr) * | 2009-12-25 | 2019-01-22 | Tomoyuki Igawa | Procede de modification de polypeptide pour purifier un multimere de polypeptide |
| SMT202000031T1 (it) * | 2010-06-09 | 2020-03-13 | Genmab As | Anticorpi contro cd38 umano |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| BR112013023918A2 (pt) * | 2011-03-25 | 2016-12-13 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural |
| AU2013322710A1 (en) * | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| DK2914302T3 (en) * | 2012-11-05 | 2017-04-10 | Morphosys Ag | RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT |
| JP2016538275A (ja) | 2013-11-04 | 2016-12-08 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造 |
-
2015
- 2015-11-02 MA MA040894A patent/MA40894A/fr unknown
- 2015-11-03 MX MX2017005814A patent/MX2017005814A/es unknown
- 2015-11-03 KR KR1020177015252A patent/KR102760422B1/ko active Active
- 2015-11-03 MY MYPI2017701499A patent/MY186929A/en unknown
- 2015-11-03 NZ NZ732019A patent/NZ732019A/en unknown
- 2015-11-03 WO PCT/EP2015/075628 patent/WO2016071355A1/fr not_active Ceased
- 2015-11-03 CA CA2965745A patent/CA2965745C/fr active Active
- 2015-11-03 EP EP15790129.9A patent/EP3215541A1/fr not_active Withdrawn
- 2015-11-03 EA EA201790961A patent/EA039658B1/ru unknown
- 2015-11-03 CN CN201580072196.8A patent/CN107207596A/zh active Pending
- 2015-11-03 PE PE2017000802A patent/PE20171041A1/es unknown
- 2015-11-03 BR BR112017009263-8A patent/BR112017009263A2/pt not_active Application Discontinuation
- 2015-11-03 AU AU2015341884A patent/AU2015341884B2/en active Active
- 2015-11-03 SG SG11201703313SA patent/SG11201703313SA/en unknown
- 2015-11-03 JP JP2017542319A patent/JP2018501297A/ja active Pending
- 2015-11-03 HK HK18103440.0A patent/HK1244014A1/zh unknown
-
2017
- 2017-04-23 IL IL251848A patent/IL251848A0/en unknown
- 2017-05-02 CL CL2017001090A patent/CL2017001090A1/es unknown
- 2017-05-03 PH PH12017500819A patent/PH12017500819A1/en unknown
- 2017-05-26 CO CONC2017/0005240A patent/CO2017005240A2/es unknown
-
2019
- 2019-07-23 JP JP2019135318A patent/JP2019214582A/ja active Pending
-
2021
- 2021-08-02 JP JP2021126392A patent/JP7403505B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7403505B2 (ja) | 2023-12-22 |
| MY186929A (en) | 2021-08-26 |
| CA2965745A1 (fr) | 2016-05-12 |
| JP2019214582A (ja) | 2019-12-19 |
| KR20170078831A (ko) | 2017-07-07 |
| KR102760422B1 (ko) | 2025-02-03 |
| AU2015341884A1 (en) | 2017-06-08 |
| CA2965745C (fr) | 2023-12-05 |
| JP2018501297A (ja) | 2018-01-18 |
| SG11201703313SA (en) | 2017-05-30 |
| NZ732019A (en) | 2022-07-29 |
| IL251848A0 (en) | 2017-06-29 |
| PE20171041A1 (es) | 2017-07-19 |
| MX2017005814A (es) | 2017-08-02 |
| CL2017001090A1 (es) | 2018-01-05 |
| BR112017009263A2 (pt) | 2018-01-30 |
| HK1244014A1 (zh) | 2018-07-27 |
| CN107207596A (zh) | 2017-09-26 |
| EP3215541A1 (fr) | 2017-09-13 |
| JP2021184722A (ja) | 2021-12-09 |
| CO2017005240A2 (es) | 2017-10-31 |
| WO2016071355A1 (fr) | 2016-05-12 |
| EA039658B1 (ru) | 2022-02-22 |
| EA201790961A1 (ru) | 2017-10-31 |
| PH12017500819A1 (en) | 2017-10-02 |
| AU2015341884B2 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40894A (fr) | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production | |
| HUS2500002I1 (hu) | Újszerû anti-PD-L1 antitestek | |
| EP3706784A4 (fr) | Compositions et procédés de production de lymphocytes t | |
| IL252467A0 (en) | Heterodimeric antibodies that bind cd3 and cd38 | |
| IL255727A (en) | Novel anti-pd-l1 antibodies | |
| IL248007A0 (en) | Bispecific antibodies that bind to cd38 and cd3 | |
| MA40889A (fr) | Immunoglobulines héréro-dimériques reciblant des lymphocytes | |
| EP3397263A4 (fr) | Procédés de production de lymphocytes t et lymphocytes t ainsi produits | |
| SG10201603721TA (en) | Anti-CTLA-4 Antibodies | |
| EP2991646A4 (fr) | Procédés et compositions pour augmenter les lymphocytes t cd4+ régulateurs | |
| SG11201705552QA (en) | Anti-pd-l1 antibodies | |
| EP3340786A4 (fr) | Production améliorée d'immunoglobulines | |
| LT3223845T (lt) | Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20 | |
| MA41375A (fr) | Anticorps igg bispécifiques et leurs procédés de préparation | |
| EP3515503A4 (fr) | Lymphocytes modifiés | |
| FI20155385A7 (fi) | Menetelmät tuotteiden jatkuvaksi tuottamiseksi mikro-organismeista | |
| MA42829A (fr) | Compositions dérivées de placenta et procédés pour les produire | |
| MA39915A (fr) | Composés de pladiénolide pyridine et leurs procédés d'utilisation | |
| EP3368087A4 (fr) | Produit de scellement bioadhésif composite | |
| MA44517A (fr) | Compositions d'immunoglobuline intraveineuse recombinante (rivig) et leurs procédés de production et d'utilisation | |
| DK3250491T3 (en) | Product turner and placer | |
| EP3393269A4 (fr) | Compositions de protéines végétales fermentées procédés pour les produire | |
| EP3282919C0 (fr) | Concept de conditionnement pour produits solides | |
| MA45831A (fr) | Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation | |
| EP3340979A4 (fr) | Compositions et procédés pour la sensibilisation de parasites à un médicament |